Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
Thyrocare Technologies reported a strong Q1 FY27, with revenue rising 24% YoY to ₹240.02 crore and net profit increasing 34% YoY to ₹51.33 crore. EBITDA also grew 34%, supported by margin expansion and higher test volumes, while the stock gained 7% following the results announcement.
Thyrocare Technologies’ share price was trading at ₹584.40 on July 23, 2026, up 7% for the day. Trading volume stood at 48.70 lakh shares compared with the 30-day average volume of 5.36 lakh shares, a near ninefold surge that represented a positive market reaction following the company's quarterly results announcement.
Thyrocare reported consolidated revenue of ₹240.02 crore for the quarter ended June 30, 2026, marking 24% growth YoY. More notably, the company converted that topline momentum into healthy bottomline expansion, with net profit climbing 34% YoY to ₹51.33 crore.
The Pathology segment was the primary engine of growth, with revenues rising 26% YoY during the quarter. Within that segment, franchise revenue grew 27% YoY while partnership revenue posted 26% growth, suggesting that Thyrocare's distributed network model is gaining traction across both channels simultaneously.
EBITDA increased 34% YoY to ₹77.27 crore, with margin expansion driven by better operating leverage as test volumes scaled. Profit before tax (PBT) rose 34.5% YoY to ₹67.58 crore. Gross margin also improved during the quarter.
Beyond the financials, Thyrocare reinforced its standing as India's largest diagnostic test volume processor, handling 55.2 million tests in Q1 FY27, up 28% YoY. That scale is not incidental; it underpins both the cost structure and the company's ability to maintain quality consistency across a sprawling network.
On quality, the company maintained Six Sigma standards, reducing complaints per million tests to 3.1, down 24% YoY. Its average turnaround time from sample receipt stood at 3.37 hours, a metric the company notes makes it India's first diagnostic chain to achieve this benchmark.
Thyrocare has been broadening its service profile beyond routine pathology. The company has moved into Specialty Diagnostics, beginning with Allergy and Genomics testing, and has been progressively expanding its specialty test portfolio. The focus, according to management, is on building clinical trust through scientific rigour and faster turnaround times, rather than simply adding tests.
Commenting on the quarter, Rahul Guha, MD and CEO of Thyrocare Technologies, said, “Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India."
Thyrocare Technologies Limited is India's first fully automated laboratory chain with a PAN India presence. The company serves patients, healthcare providers, insurance companies, pharmaceutical companies, franchisees, laboratories and hospitals. As of Q1 FY27, it operated a franchise network of approximately 11,700 outlets and processed 55.2 million diagnostic and screening investigations during the quarter.
Thyrocare during Q1 FY27 has been characterised by efficient execution in terms of both financials and operations. Growth in pathology business as well as an improved suite of specialty diagnostics and efficiency have helped the company in earning momentum. Scaling up the business network going forward while ensuring quality will continue to be important for the company.
Source: Dalal Street Investment Journal (DSIJ), NSE, BSE
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading